Biotech and Pharmaceutical
News & Jobs

Search the Site

Employers
Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

News | News By Subject | News by Disease | News By Date | Search News

Get Our Industry eNewsletter FREE

email:

Merck & Co., Inc. (MRK) Swings to Profit on Fewer Charges, Sales Growth

2/3/2012 6:58:25 AM

Merck & Co. swung to a fourth-quarter profit from a year-earlier loss that was weighed down by an asset write-down for a drug-research setback, while sales inched up 2%. The Whitehouse Station, N.J., drug maker issued a forecast for full-year 2012 results that leaves room for earnings growth, while sales are expected to be flat or down due to the impending loss of U.S. patent protection for its top-selling drug, the asthma and allergy treatment Singulair. The expected generic competition for Singulair after the patent expiration in August will put Merck in a position similar to that of competitors Pfizer Inc. and Eli Lilly & Co., which this week posted declining sales and earnings for the fourth quarter as a result of recent patent losses for top drugs.

Read at Wall Street Journal

Read at Barron's Online

Read at Washington Post

Read at Reuters

Read at News Release